PBT for Medical Devices: Sterilisation Methods and What Each One Does to the Part

Polybutylene terephthalate (PBT) in medical device housings, drug-delivery actuator components, and surgical instrument bodies is selected for dimensional stability, low moisture absorption, and resistance to repeated mechanical loading. The unreinforced grade typically exhibits a tensile modulus of 2.6 GPa per ISO 527-2, flexural strength near 85 MPa per ISO 178, and water absorption below 0.1% after 24 h immersion per ISO 62:2008. Production-scale moulding of PBT medical parts commonly uses screw L/D ratios of 20:1 to 25:1, back pressures of 5–10 bar, barrel temperatures of 240–260°C, and tool temperatures of 40–80°C. Resin is pre-dried at 120°C for 4 h to a moisture content below 0.02%. These initial conditions establish molecular weight distribution and crystallinity that determine subsequent sterilisation response. For medical use, biological evaluation follows ISO 10993-1, while sterilisation validation follows process-specific ISO standards.

PBT is semi-crystalline with a melting point near 223°C and a crystallinity that can be adjusted from 25% to 50% through mould temperature and cooling rate. Crystallinity controls sterilisation response: a higher crystalline fraction reduces steam and ethylene oxide permeability but can lower impact strength. Medical PBT grades are therefore frequently formulated with nucleating agents and heat stabilizers; any additive must be assessed under ISO 10993-12 extraction conditions. The polymer is selected for chemical resistance and low cold-flow, but it is less hydrolytically stable under moist heat than polypropylene or polyphenylene sulfone.

How Does Saturated Steam at 121°C and 134°C Alter PBT Molecular Weight?

Steam autoclaving under ISO 17665:2014 exposes the part to saturated steam at 121°C for 15–30 min or 134°C for 3–4 min, typically at gauge pressures of 1.0–2.1 bar. The dominant reaction is hydrolysis of the ester linkages in the 1,4-butanediol–terephthalate backbone. Water vapour diffuses preferentially into the amorphous regions once the part temperature exceeds the glass transition range of 50–60°C; chain scission releases terephthalic acid and 1,4-butanediol, increasing carboxylic acid end-group concentration. The liberated acid groups autocatalyse further hydrolysis. Because hydrolysis follows first-order kinetics with respect to water concentration and polymer chain ends, the practical effect is a progressive reduction in number-average molecular weight, a fall in melt viscosity, and a loss of elongation at break. In moulded PBT parts with thin sections below 2 mm, a single autoclave cycle may produce acceptable property retention, but repeated cycles at 134°C can embrittle unfilled components because the continuous amorphous phase undergoes scission before the crystalline regions are significantly affected. Glass-fibre-reinforced PBT can show surface whitening and interfacial attack at the fibre–matrix boundary because wicking along glass fibres accelerates local water ingress. Published data for specific cycle count in medical PBT grades is limited; device manufacturers commonly restrict saturated steam exposure to components with low mechanical load and require tensile impact testing after the maximum number of planned cycles.

Hydrolysis is heterogeneous in thick sections because water penetration is diffusion-limited. At 121°C, a PBT part with wall thickness of 3 mm may develop a brittle surface layer over a tougher core, producing a molecular-weight gradient. This gradient can be characterised by microtome sectioning and intrinsic viscosity measurement in 60:40 phenol–tetrachloroethane at 25°C, where intrinsic viscosity is a sensitive indicator of chain scission. Differential scanning calorimetry can also show a reduced cold crystallisation temperature after autoclaving because shorter chains crystallise more readily. The resulting part-level property is a brittle skin over a tougher core, which can cause premature crack initiation under flexural fatigue. Therefore, autoclave validation should test not only tensile strength but also flexural strain at break and instrumented impact energy after conditioning at maximum cycle count. Hydrolysis-resistant PBT grades may use polymeric carbodiimide additives that react with free carboxylic acid end groups, but such additives must be reviewed for biocompatibility under ISO 10993-1.

Validation experience on production-scale autoclaves shows that load configuration alters local steam penetration and condensate drainage. Dense PBT components packed in trays can experience lower heat-up rates than porous loads; thermocouple mapping and biological indicators alone do not detect hydrolytic damage. The physical testing plan should therefore incorporate reference coupons moulded from the same lot and sterilised at the worst-case location. Batch-to-batch molecular weight variation should be included in the acceptance margin because resin lot history influences autocatalytic hydrolysis rate.

Under gamma irradiation at 25–40 kGy validated to ISO 11137-2, PBT components absorb photon energy that generates free radicals in both amorphous and crystalline phases. The immediate response is dominated by abstraction and scission reactions along the aliphatic butanediol segment; the aromatic terephthalate group provides some radiation resistance through energy dissipation. Dose application at a commercial cobalt-60 facility occurs over several hours, allowing oxygen diffusion into the polymer surface. This produces peroxy radicals and subsequent carbonyl oxidation products. Unfilled PBT typically survives a single 25 kGy dose with limited loss of tensile strength; however, yellowness index increases and elongation at break may decline substantially in thin films below 0.5 mm. Glass-fibre-reinforced PBT can show a small loss in flexural strength after 50 kGy because radiation-induced oxidation at the fibre sizing interface reduces load transfer.

Electron beam sterilisation at the same nominal dose range but with dose rates of 10 kGy/s or higher limits oxygen diffusion during energy deposition; the practical consequence is that E-beam-treated PBT can exhibit less oxidative discolouration immediately after sterilisation but may still develop post-irradiation oxidation over the following weeks. Dose mapping using alanine dosimeters under ISO 11137-3 is required for both gamma and E-beam because dose distribution across high-density PBT components can vary by more than 10% depending on part mass and orientation. Post-irradiation aging at room temperature can continue for several weeks; acceptance criteria should therefore include mechanical testing at a defined post-sterilisation interval.

Ethylene Oxide Diffusion, Residue Desorption, and the 1,4-Butanediol Segment

Ethylene oxide sterilisation is performed at gas concentrations of 300–750 mg/L, relative humidity of 30–80%, and chamber temperatures of 37–55°C, followed by heated aeration to remove absorbed sterilant. The process standard is ISO 11135:2014, with residue limits under ISO 10993-7. For PBT, the low process temperature is below the glass transition range of 50–60°C; chain mobility is restricted, and thermal degradation is not the primary concern. EtO penetrates the amorphous phase and adsorbs onto ester and aromatic sites. Residual EtO and ethylene chlorohydrin levels after aeration depend on part thickness, wall geometry, and the solubility of EtO in the PBT matrix. Thin-walled PBT parts below 1.5 mm typically desorb more rapidly than thicker sections. Because PBT does not require steam or high temperature, EtO is often selected for drug-delivery actuator components and electronic housing subassemblies where hydrolytic or thermal damage is unacceptable. The operational boundary is aeration time: cycle validation must demonstrate that residual EtO falls below the ISO 10993-7 limit for the device patient contact category. PBT with high crystallinity retains less EtO because sorption occurs predominantly in the amorphous phase; a mould temperature of 60–80°C may be used to stabilise crystallinity and reduce sterilant uptake.

Cycle development for PBT components must address two interacting variables: EtO sorption during exposure and desorption during aeration. Increasing aeration temperature to 50–55°C accelerates desorption but must not exceed the thermal deflection limit of the component. Gas chromatography with headspace sampling after extraction is used to quantify residual EtO and ethylene chlorohydrin; the acceptable limit is not a single universal value but depends on the device contact category defined in ISO 10993-7. Production-scale loads with high PBT surface area may require extended aeration beyond 24 h if wall thickness exceeds 3 mm or if the load contains tight interfaces.

When Vaporized Hydrogen Peroxide Contacts PBT at 45–55°C

Vaporized hydrogen peroxide (VH₂O₂) sterilisation under ISO 22441:2022 exposes the part to H₂O₂ vapour at concentrations of 1–2 mg/L and chamber temperatures of 45–55°C, often with sequential plasma phases depending on the equipment. For PBT, the process temperature is below the glass transition range, so dimensional movement is minimal. The primary interaction is oxidative attack at the surface and near-surface amorphous regions. Peroxide-derived hydroxyl and peroxy radicals can abstract hydrogen from the butanediol segment, forming carbonyl and hydroperoxide species. This surface oxidation is usually shallow, on the order of a few micrometres after a single cycle, but repeated cycles may increase surface polarity and reduce gloss. The crystalline domains are less permeable to the vapour, limiting bulk oxidative damage. Glass-fibre-reinforced PBT can exhibit slight whitening at exposed fibre ends because oxidation at the matrix surface changes refractive index and reveals fibre boundaries. Validation should include Fourier-transform infrared spectroscopy for carbonyl index increase and tensile testing per ASTM D638-14 or ISO 527-2 after the maximum number of cycles. Published data for specific PBT medical grades under repeated VH₂O₂ is limited; the main operational boundary is compatibility of adjacent metal inserts and conductive elements, which may catalyse peroxide decomposition.

Low-temperature hydrogen peroxide sterilizers typically operate with deep vacuum pulses, which can subject sealed PBT components to pressure differentials. Devices with internal cavities or semipermeable membranes should be checked for pressure-induced distortion because PBT thin sections below 1 mm can flex under vacuum. If plasma phases are used, the part is exposed to radio-frequency or microwave energy; metallic inserts may concentrate energy and accelerate local peroxide breakdown. Validation should therefore include functional testing of assemblies, not only isolated moulded plaques.

When dry heat sterilisation at 160–180°C for 60–120 min is used, as described in ISO 20857, the dominant process is thermo-oxidative degradation rather than hydrolysis. Unfilled PBT has a heat deflection temperature under 1.8 MPa of approximately 55–65°C per ISO 75-2; therefore, any load-bearing feature can deform or stress-relax during dry heat exposure even though the melting point is 223°C. The ester groups undergo thermal oxidation at the aliphatic butanediol segment, leading to discolouration, surface embrittlement, and a measurable decline in elongation at break. Dry heat is rarely used for PBT medical components because the required temperature is above the glass transition and close to the practical upper limit for dimensional stability. If dry heat is unavoidable, unfilled PBT should be annealed before exposure at 120–130°C to stabilise crystallinity and reduce subsequent shrinkage.

Annealing increases crystallinity and can reduce subsequent shrinkage during dry heat exposure. However, annealing also consumes part of the elongation capacity of the material because amorphous tie molecules reorganise; the final part may become stiffer. Dry heat sterilisation should therefore be combined with upper-temperature mechanical testing to confirm that the device remains compliant at use conditions.